Determination of bioactive compounds, antioxidant and anticancer activities of Tuckeroo (Cupaniopsis anacardioides) fruits

Ngoc Minh Quynh Pham1,2 · Quan V. Vuong1 · Jennette A. Sakoff3 · Michael C. Bowyer1 · Van Anh Le1 · Christopher J. Scarlett1

Received: 7 May 2022 / Accepted: 15 August 2022 / Published online: 3 September 2022
© The Author(s) 2022

Abstract
This study aimed to determine the phytochemical, antioxidant, and anticancer activities of the crude extract and its fractions of Cupaniopsis anacardioides. The results showed that total phenolic content (TPC), their secondary metabolites (flavonoids—TFC; proanthocyanidins—TPro), and antioxidant activity were significantly different between the crude extract and its fractions. The butanol fraction (F3) had the highest levels of TPC, TFC, and TPro, followed by the crude extract, aqueous fraction (F4), dichloromethyl fraction (F2), and hexane fraction (F1). High-Pressure Liquid Chromatography (HPLC) analysis revealed 14 major bioactive compounds were identified in the C. anacardioides extract. Further analysis showed F3 fraction contained the highest levels of the major bioactive compounds, while F1 fraction had the lowest. A similar pattern was observed for antioxidant activities. The crude extract, F3 and F4 fractions were further tested for cytotoxicity against 10 cancer cell lines, including HT29 (colon); U87, SJG2 (glioblastoma); MCF-7 (Breast); A2780 (ovarian); H460 (lung); A431 (skin); Du145 (prostate); BE2-C (neuroblastoma); MIA PaCa-2 (pancreas); and one non-tumour-derived normal breast cell line (MCF10A). Except for Du145 (prostate), the crude extract, F3 and F4 fractions inhibited the cancer cell lines at 100 µg/mL, with F3 possessing greater activity against these cancer cell lines. Future studies are recommended to isolate and identify the major bioactive compounds of the F3 fraction, and further tested their impact against cancer cell lines. This could identify the potential of anticancer agents from C. anacardioides.

Keywords Tuckeroo · Fruits · Phytochemical · Antioxidant · Anticancer · Cytotoxic activities

Introduction
Plant-derived phytochemicals have been used as a natural medicine for the treatment of diseases for thousands of years (Hartwell 1982; Tabor 2002). Approximately 60% of commercial pharmaceutical products are related to various plant species, and are used by ~ 80% of rural populations worldwide. This demonstrates that plant biological compounds are indispensable agents in the prevention and treatment of human diseases (Cragg and Newman 2005). However, only 10% of the ~ 250,000 plant species have been investigated for their medicinal potential (Q. Vuong et al. 2014). Therefore, seeking, screening, and identifying such phytochemicals are essential for exploring a novel and an effective therapeutic agent. In particular, cancer diseases are known as largely untreatable diseases due to the toxicity of modern chemotherapy and cancer cell resistance to anticancer agents (Duell et al. 2012; Hidalgo 2010; Li and Leung 2014; Neoptolemos et al. 2004; Scarlett and Vuong 2015). Therefore, there is an urgent need to identify the effective prevention and treatment methods for these diseases.

The Tuckeroo (Cupaniopsis anacardioides) is one of Australian nature plant, its fruit performed in eye-catching colour, orange, was used as a natural food source by Aboriginal people in Australia for hundreds of decades ago (Everitt
and Alaniz 1981). Previous study (Pham et al. 2017) was indicated Tuckeroo fruits possess a high level of phenolics compounds and strong antioxidant capacity that could be a valuable promising for anticancer treatments.

This study aimed to investigate phytochemicals, antioxidant properties of the extracts prepared from Tuckeroo fruits and further test their potential anticancer properties using 10 different cancer cell lines.

**Materials and methods**

**Plant materials**

Ripe fruits of the Tuckeroo (*Cupaniopsis anacardioides*) were collected from Terrigal Beach (33° 26' 52.8396" S 151° 26' 40.0596" E) and Avoca Beach (33° 27' 54" S 151° 26' 6" E), New South Wales, Australia in Summer (Tuckeroo fruits’ season). After collection, fruits were immediately taken to the laboratory of the University of Newcastle and freeze-dried using a freeze dryer (FD3 freeze dryer (Thomas Australia Pty. Ltd., Seven Hills, NSW, Australia). The dried fruits were then ground into powder (less than 1.4 mm in particle size) using a blender (John Morris Scientific, Chatswood, NSW, Australia) and were preserved at –20 °C for further analysis.

**Preparation of crude *C. anacardioides* extract and its fractions**

The crude extract and its fractions were prepared as shown in Fig. 1. The crude extract was obtained by extraction under optimal ultrasonic extraction conditions described in our previous study (Pham et al. 2019). Dried fruit powder (5 g) was extracted in 100 mL acetone 50% using an ultrasonic bath (Soniclean, 220 V, 50 Hz and 250 W, Soniclean Pty Ltd., Thebarton, Australia) set at 150 W, 40 °C for 40 min. After extraction, the extract was centrifuged at 4000 rpm for 10 min at 5 °C (Centrifuge, Beckman J2-MC, Palo Alto, CA, USA) to remove unwanted particles. The extract was then concentrated at low pressure using an evaporator (Buchi Rotavapor B-480, Buchi, Australia, Noble Park, VIC, Australia) and finally 72 h of freeze-dried at –80 °C to obtain a crude powdered extract using a FD3 freeze dryer (Thomas Australia Pty. Ltd., Seven Hills, NSW, Australia).

Four sub-fractions, including hexane fraction (F1), dichloromethyl fraction (F2), butanol fraction (F3), and aqueous fraction (F4), were subsequently prepared from the crude powdered extract using a liquid–liquid extraction technique. The crude powdered extract was diluted into deionized water with the ratio of 2:50 (g/mL). Hexane, dichloromethyl and butanol solvents were then applied with 1:1 ratio to the diluted crude extract to obtain F1, F2, F3, and F4, as shown in (Fig. 1). The four fractions were then evaporated and freeze-dried to form dried fractions for further analysis.

**Determination of bioactive compounds**

The crude powdered extract and its fractions were re-dissolved in 50% methanol (5 g/100 mL). The extracts were then vortexed and sonicated to ensure solubility. Total phenolic content (TPC) and their secondary metabolites including flavonoids (TFC) and proanthocyanidins (TPro) were determined according to previously described methods (Pham et al. 2017; Škerget et al. 2005). TPC was absorbed at 765 nm, using gallic acid as a standard and its value was expressed as milligrams of gallic acid equivalents per gram of dried sample (mg GAE/g DW). TFC and TPro were
measured at 510 and 500 nm, respectively, using catechin as a standard and their values were recorded as milligrams of catechin equivalents per gram of dried extract (mg CAE/g DW).

HPLC analysis was applied for determination of major individual compounds in the crude extract and its fractions. A Shimadzu HPLC system (Shimadzu, Tokyo, Japan) equipped with a column (Prodigy 5 µ ODS3 100A; 250×46 mm 5 µm) and UV detection (UV–Vis detector SPD-20AV) set at 210 and 280 nm was used to isolate the majority of bioactive components. A volume of 50 µL sample was injected into the column, using an auto injector (SIL-20A HT). The flow rate was set at 1 mL/min, and consisted 0.1% (v/v) formic acid (solvent A) and absolute acetonitrile (solvent B). The gradient was set as follows: 0–30 min, 20% B; 30–55 min, 60% B; 55–65 min, 100% B; 65–75 min, 30% B; 75–85 min, 0% B and 85–90 min, 0% B. Gemcitabine 1 mM was used as a standard to quantify major compounds in the crude extract and its fractions (Vuong 2015). The results were expressed as mg of gemcitabine equivalents to gram of dried extract (mg GCE/g).

**Determination of the antioxidant activities**

To fully reflect the antioxidant capacity from Tuckeroo crude extract and its fractions, four different assays were used, including the DPPH radical scavenging assay, ABTS radical scavenging assay, ferric reducing antioxidant power (FRAP), and cupric-reducing antioxidant capacity (CUPRAC) assays.

DPPH (2, 2-diphenyl-1-picrylhydrazyl) was assessed based on the method as described by Brand-Williams et al. (1995). ABTS [2, 2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid)] was determined according to the previous method reported by Thaipong et al. (2006). The FRAP assay was used based on a previous method (Benzie and Strain 1996). CUPRAC was assessed according to Apak et al. (2004). The absorbance was measured at 515, 734, 593, and 450 nm, respectively, using an UV spectrophotometer (Cary 50 Bio Varian, Australia). Trolox was used as a standard curve and the results were expressed as mg of trolox equivalents per g of dried sample (mg TE/g DS).

**Growth inhibition**

Cytotoxicity of the Tuckeroo extracts and their semi-purified fractions were assessed in vitro throughout a panel of cancer cell lines including HT29 (colon); U87, SJ-G2 (glioblastoma); MCF-7 (Breast); A2780 (ovarian); H460 (Hsu et al. 2003); A431 (Raskin et al.); Du145 (Gundem et al. 2015); BE2-C (neuroblastoma); MIA PaCa-2 (pancreas); and one non-tumour-derived normal breast cell line (MCF10A). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was applied as previously described by Vuong et al. (2015). All tested cells were initial seeded in the 96-well plates with a density of 2500 to 4000 cells per well. Then, they were incubated for 24 h to reach the logarithmic growth. The cytotoxicity of the Tuckeroo extract and its fractions at the concentration of 100 µg/mL were assessed after 72 h of incubation, using MTT assay. Growth inhibition was measured at 540 nm by the optical density differences between these values on day 0 and at the end of treatment.

**Results and discussion**

**Total phenolic content, flavonoids, and proanthocyanidins**

The content of phenolic compounds and their secondary metabolites were significantly different in the crude extract and its fractions (Fig. 2). The highest levels of TPC, TFC, and TPro were found in butanol fraction (F3), followed by the crude extract, aqueous fraction (F4), and dichloromethyl fraction (F2). Hexane fraction (F1) had the lowest levels of TPC, TFC, and TPro. Levels of TPC, TFC, and TPro of F3 were approximately twofold higher than those of the crude extract and over tenfold higher than those of F1. Our findings were similar to previous studies, which reported that the...
Antioxidant activity of the crude extract and its fractions

Antioxidant activity of the crude extract and its fractions are presented in (Fig. 4). A similar pattern to the total phenolic compounds was observed for the antioxidant activities. The results from the four antioxidant assays showed that F3 had the highest antioxidant activity (ABTS-1570.49 mg TE/g; DPPH-1328.97 mg TE/g; CUPRAC-1529.4 mg TE/g; FRAP-764.7 mg TE/g). This was followed by the crude extract and other fractions, while the hexane fraction had the lowest level of antioxidant activity. Previous studies also found that the butanol fraction (F3) had the highest level of antioxidant activity. The results from the four antioxidant assays showed that the butanol fraction (F3) had the highest level of antioxidant activity. The results from the four antioxidant assays showed that the butanol fraction (F3) had the highest level of antioxidant activity.

The pattern to the phenolics, and variation in antioxidant activities of different fractions can be explained by different levels in phenolic compounds, which are the major antioxidants (antioxidant contributors) in the Tuckeroo extracts (Pham et al. 2017). Plant polyphenols have been known as antioxidants, they have also been reported to be potential anticancer substances and antioxidant activity have been linked with anticancer properties (Grigalius and Petrikaite 2017). Therefore, only the butanol fraction (F3), crude extract, and aqueous fraction (F4), which had potent antioxidant activities, were applied for further testing of their cytotoxicity.

**Anticancer activities**

The proportions of cell growth inhibition of the Tuckeroo extract and its butanol and aqueous fractions are shown in Table 2. The results indicated that, except for the cell Du145—prostate cancer cell line, the crude extract (100 µg/mL) could inhibit growth from 33 to 100% for the tested cancer cell lines. The F3 possessed the higher cytotoxicity and growth inhibitory activity in comparison with the crude extract, and F4 within almost tested cancer cell lines, except for breast (MCF-7) and pancreas (MIA PaCa-2) cells, providing an illustration for a good correlation between phytochemicals, antioxidant properties, and anticancer activity. These findings were in agreement with the investigation on C. roseus stems by Pham et al. (2018), which reported that the n-butanol fraction had a stronger cytotoxic activity than aqueous fraction. However, prostate cancer cells were not inhibited under the concentration of 100 µg/mL, while 100% growth inhibition of glioblastoma cancer cell (SJ-G2) was observed. As such, a rigorous elucidation of individual component cytotoxicity should be assessed on these cancer cell lines to obtain a more comprehensive understanding of this promising plant material.

Table 3 shows the minimum concentration of the crude extract and its semi-purified fractions (µg/mL) required to inhibit the growth of 50% of cancer cells (GI50). The lower the values of the GI50, the stronger the anticancer activity of the tested extracts. Data from Table 3 reveal that 28–169 (µg/mL) of F3 inhibited growth by 50% of tested cancer cell lines, followed by 37–196 (µg/mL) of the crude extract and 38–200 (µg/mL) of F4. Whereas, GI50 values of *Eucalyptus robusta* were ranged from 74 to > 200 (µg/mL), reported by Bhuyan et al. (2017), indicated weaker cytotoxic activity than observed for the Tuckeroo extracts. Interestingly, the cytotoxic activities of the crude extract and both F3 and F4 were strongest against pancreas cancer cells (MIA PaCa-2). The GI50 were the greatest for prostate cancer cells (169, 196, and > 200 µg/mL), which was much higher than that of...
the other tested cancer cell lines. These data were in line with the percentage of growth inhibition outcomes, which indicated that prostate cancer cells were not inhibited at the concentration of 100 µg/mL. Consequently, identification and isolation phytochemical constituents from these extracts are recommended in future research.

**Conclusions**

The Tuckeroo (*Cupaniopsis anacardioides*) crude extract and its fractions were shown to be a good natural source of phytochemicals with strong antioxidant properties.
Fourteen major bioactive compounds were isolated within the three extracts. The butanol fraction (F3) had the greatest levels of total bioactive compounds with strongest antioxidant activity. This fraction also had better anticancer activity compared to the other fractions.

### Table 1: Concentration of major bioactive compounds of the Tuckeroo crude extract and its fractions

| Compounds | Crude extract | F1 | F2 | F3 | F4 |
|-----------|---------------|----|----|----|----|
| I (mg GCE/g) | 3.13 ± 0.00<sup>b</sup> | 1.22 ± 0.00<sup>d</sup> | 4.33 ± 0.00<sup>a</sup> | 1.01 ± 0.00<sup>c</sup> | 2.49 ± 0.00<sup>e</sup> |
| II (mg GCE/g) | 7.78 ± 0.00<sup>b</sup> | 3.45 ± 0.00<sup>c</sup> | 9.81 ± 0.00<sup>a</sup> | 0.67 ± 0.00<sup>e</sup> | 2.97 ± 0.00<sup>d</sup> |
| III (mg GCE/g) | 3.02 ± 0.00<sup>e</sup> | ND | 3.87 ± 0.00<sup>a</sup> | 3.98 ± 0.00<sup>a</sup> | 2.06 ± 0.00<sup>e</sup> |
| IV (mg GCE/g) | 5.72 ± 0.00<sup>c</sup> | ND | 30.86 ± 0.00<sup>e</sup> | 12.15 ± 0.00<sup>ab</sup> | 1.44 ± 0.00<sup>d</sup> |
| V (mg GCE/g) | 17.82 ± 0.00<sup>b</sup> | ND | 3.21 ± 0.00<sup>d</sup> | 34.56 ± 0.00<sup>a</sup> | 7.71 ± 0.00<sup>c</sup> |
| VI (mg GCE/g) | 30.16 ± 0.00<sup>b</sup> | 3.30 ± 0.00<sup>b</sup> | 9.68 ± 0.00<sup>c</sup> | 70.6 ± 0.00<sup>c</sup> | 8.89 ± 0.00<sup>c</sup> |
| VII (mg GCE/g) | 21.46 ± 0.00<sup>b</sup> | ND | 6.29 ± 0.00<sup>d</sup> | 45.95 ± 0.00<sup>a</sup> | 8.07 ± 0.00<sup>c</sup> |
| VIII (mg GCE/g) | 16.95 ± 0.00<sup>b</sup> | 0.96 ± 0.00<sup>e</sup> | 3.08 ± 0.00<sup>d</sup> | 26.89 ± 0.00<sup>a</sup> | 8.75 ± 0.00<sup>c</sup> |
| IX (mg GCE/g) | 14.9 ± 0.00<sup>b</sup> | ND | 2.66 ± 0.00<sup>d</sup> | 25.45 ± 0.00<sup>a</sup> | 5.66 ± 0.00<sup>c</sup> |
| X (mg GCE/g) | 9.03 ± 0.00<sup>b</sup> | ND | 2.56 ± 0.00<sup>d</sup> | 15.23 ± 0.00<sup>a</sup> | 3.46 ± 0.00<sup>c</sup> |
| XI (mg GCE/g) | 5.42 ± 0.00<sup>b</sup> | ND | 2.75 ± 0.00<sup>c</sup> | 14.30 ± 0.00<sup>a</sup> | 2.52 ± 0.00<sup>d</sup> |
| XII (mg GCE/g) | 2.25 ± 0.00<sup>b</sup> | 2.12 ± 0.00<sup>d</sup> | 6.00 ± 0.00<sup>c</sup> | 2.19 ± 0.00<sup>c</sup> | 2.25 ± 0.00<sup>d</sup> |
| XIII (mg GCE/g) | 0.90 ± 0.00<sup>c</sup> | ND | 3.63 ± 0.00<sup>c</sup> | 0.90 ± 0.00<sup>c</sup> | 0.91 ± 0.00<sup>c</sup> |
| XIV (mg GCE/g) | 12.71 ± 0.00<sup>d</sup> | 13.05 ± 0.00<sup>b</sup> | 20.57 ± 0.00<sup>a</sup> | 12.74 ± 0.00<sup>c</sup> | 12.66 ± 0.00<sup>c</sup> |
| Total (mg GCE/g) | 151.26 | 24.10 | 109.31 | 266.62 | 69.83 |

Data are means ± standard deviations. Data in the same row sharing different superscript letters are significantly different at p < 0.05. ND: no data.

### Table 2: Cell growth inhibition activity (%) of the Tuckeroo extract and its fractions

| Cell line | Cancer cell types | Crude extract | F3 | F4 |
|-----------|-------------------|---------------|----|----|
| HT29      | Colon             | 47 ± 3<sup>b</sup> | 58 ± 2<sup>a</sup> | 32 ± 3<sup>c</sup> |
| U87       | Glioblastoma      | 37 ± 5<sup>a</sup> | 42 ± 10<sup>b</sup> | 23 ± 4<sup>b</sup> |
| MCF-7     | Breast            | 33 ± 6<sup>a</sup> | 27 ± 8<sup>b</sup> | 3 ± 7<sup>c</sup> |
| A2780     | Ovarian           | 81 ± 1<sup>b</sup> | 84 ± 1<sup>a</sup> | 69 ± 1<sup>c</sup> |
| H460      | Lung              | 89 ± 3<sup>b</sup> | 94 ± 1<sup>a</sup> | 81 ± 2<sup>c</sup> |
| A431      | Skin              | 74 ± 4<sup>b</sup> | 90 ± 4<sup>a</sup> | 62 ± 5<sup>c</sup> |
| Du145     | Prostate          | < 0            | < 0          | < 0          |
| BE2-C     | Neuroblastoma     | 80 ± 3<sup>c</sup> | 89 ± 2<sup>b</sup> | 86 ± 2<sup>b</sup> |
| SJ-G2     | Glioblastoma      | > 100<sup>a</sup> | > 100<sup>a</sup> | > 100<sup>a</sup> |
| MIA PaCa-2| Pancreas          | 99 ± 1<sup>a</sup> | 95 ± 1<sup>b</sup> | 99 ± 1<sup>a</sup> |
| MCF10A    | Breast (normal)   | 22 ± 7<sup>b</sup> | 54 ± 6<sup>a</sup> | < 0          |

Data are means ± standard deviations. Data in the same row sharing different superscript letters are significantly different at p < 0.05.
Table 3  GI₅₀ values

| Cell line | Cancer cell types | GI₅₀ values (µg/mL) |
|-----------|-------------------|-------------------|
|           | Crude extract     | F3                | F4                |
| HT29      | Colon             | 107 ± 6<sup>b</sup> | 89 ± 2<sup>c</sup> | 136 ± 2<sup>a</sup> |
| U87       | Glioblastoma      | 118 ± 6<sup>b</sup> | 111 ± 11<sup>b</sup> | 153 ± 9<sup>a</sup> |
| MCF-7     | Breast            | 130 ± 8<sup>c</sup> | 157 ± 22<sup>b</sup> | > 200<sup>a</sup> |
| A2780     | Ovarian           | 40 ± 2<sup>b</sup>  | 39 ± 2<sup>b</sup>  | 53 ± 2<sup>a</sup>  |
| H460      | Lung              | 48 ± 4<sup>b</sup>  | 44 ± 4<sup>c</sup>  | 57 ± 4<sup>a</sup>  |
| A431      | Skin              | 74 ± 5<sup>b</sup>  | 62 ± 4<sup>c</sup>  | 80 ± 7<sup>a</sup>  |
| Du145     | Prostate          | 196 ± 18<sup>b</sup>| 169 ± 2<sup>c</sup> | > 200<sup>a</sup> |
| BE2-C     | Neuroblastoma     | 67 ± 3<sup>a</sup>  | 52 ± 2<sup>c</sup>  | 62 ± 5<sup>b</sup>  |
| SJ-G2     | Glioblastoma      | 41 ± 2<sup>a</sup>  | 38 ± 2<sup>a</sup>  | 43 ± 4<sup>a</sup>  |
| MIA PaCa-2 | Pancreas         | 37 ± 1<sup>b</sup>  | 28 ± 2<sup>b</sup>  | 38 ± 3<sup>a</sup>  |
| MCF10A    | (Breast)          | 140 ± 6<sup>b</sup>| 99 ± 7<sup>c</sup>  | 182 ± 10<sup>b</sup>|

Data are means±standard deviations. Data in the same row sharing different superscript letters are significantly different at p < 0.05.

capacity. Therefore, future studies are recommended to purify and identify the major bioactive compounds from the butanol fraction of the Tuckeroo extract and further test their anticancer properties.

Funding  Open Access funding enabled and organized by CAUL and its Member Institutions.

Declarations

Conflict of interest  On behalf of all authors, the corresponding author states that there is no conflict of interest.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Aldadadi S, Moradi M-T, Asadi-Samani M, Lorigooini Z (2017) Antioxidant potential and total phenolic compounds of extracts and fractions of Pistasia atlantica. Int J Pharm Clin Res 9(4):293–297

Apak R, Guclu K, Ozyurek M, Karademir SE (2004) Novel total anti-oxidant activity index for dietary polyphenols and vitamins C and E, using their cupric ion reducing capability in the presence of neocuproine: CUPRAC method. J Agric Food Chem 52(26):7970–7981 (Retrieved from <Go to ISI>://WOS:000225985700037)

Benzie IF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 239(1):70–76

Bhuyan DJ, Sakoff J, Bond DR, Predebon M, Vuong QV, Chalmers AC, Scarlett CJ (2017) In vitro anticancer properties of selected Eucalyptus species. In Vitro Cell Dev Biol-Anim 53(7):604–615. https://doi.org/10.1007/s11626-017-0149-y

Brand-Williams W, Cuvelier M-E, Berset C (1995) Use of a free radical method to evaluate antioxidant activity. LWT-Food Sci Technol 28(1):25–30

Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100(1):72–79

Duell E, Lucenteforte E, Olson S, Bracchi P, Li D, Risch H, Holly E (2012) Pancreatitis and pancreatic cancer risk: a pooled analysis in the international pancreatic cancer case-control consortium (PanC4). Ann Oncol 23:2964–2970

Everitt J, Alaniz M (1981) Nutrient content of cactus and woody plant fruits eaten by birds and mammals in south Texas. Southwest Nat 26:301–305

Grigalius I, Petrikaite V (2017) Relationship between antioxidant and anticancer activity of trihydroxyflavones. Molecules 22(12):2169

Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Grigalius I, Petrikaite V (2017) Relationship between antioxidant and anticancer activity. Antioxid Redox Signal 22(12):1357–1366

Hartwell JL (1982) Plants used against cancer: a survey. Quarterman Publications, New Jersey, United States

Hidalgo M (2010) Pancreatic cancer. New England J Med 362(17):1605–1617. Retrieved from http://www.nejm.org/doi/pdf/https://doi.org/10.1056/NEJMr1003362

Hsu C-L, Chen W, Weng Y-M, Tseng C-Y (2003) Chemical composition, physical properties, and antioxidant activities of yam flours as affected by different drying methods. Food Chem 83(1):85–92

Li L, Leung PS (2014) Use of herbal medicines and natural products: an alternative approach to overcoming the apoptotic resistance of pancreatic cancer. Int J Biochem Cell Biol 53:224–236

Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey T, Lacaine F (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200–1210

Pham NMQ, Chalmers AC, Vuong QV, Bowyer MC, Scarlett CJ (2017) Characterising the Physicochemical and Antioxidant Properties of the Tuckeroo (Cupaniopsis anacardioides) Fruit. Technologies. https://doi.org/10.3390/technologies5030057

Pham HNT, Sakoff JA, Van Vuong Q, Bowyer MC, Scarlett CJ (2018) Screening phytochemical content, antioxidant, antimicrobial and cytotoxic activities of Catharanthus roseus (L.) G. Don stem extract and its fractions. Biocatal Agric Biotechnol 16:405–411

Pham NMQ, Vuong QV, Bowyer MC, Scarlett CJ (2019) Optimization of ultrasound-assisted extraction conditions for phenolic compounds and antioxidant capacity from Tuckeroo (Cupaniopsis anacardioides) fruit. Sep Sci Technol 55:1–10

Scarlett CJ, Vuong QV (2015) Plant bioactive compounds for prevention and treatment pancreatic cancer (C. J. S. a. Q. V. Vuong Ed), vol 1. Nova Science Publishers, USA

Škerget M, Kotnik P, Hadolin M, Hraš AR, Simonič M, Knez Ž (2005) Phenols, proanthocyanidins, flavones and flavonols in some plant materials and their antioxidant activities. Food Chem 89(2):191–198

Tabor K (2002) Wild about herbs. Reader’s Digest Association, Inc., New York, United States

Thaipong K, Boonprakob U, Crosby K, Cisneros-Zevallos L, Byrne DH (2006) Comparison of ABTS, DPPH, FRAP, and ORAC assays for estimating antioxidant activity from guava fruit extracts. J
Vuong QV, Hirun S, Chuen TLK, Goldsmith CD, Murchie S, Bowyer MC, Scarlett CJ (2015) Antioxidant and anticancer capacity of saponin-enriched Carica papaya leaf extracts. Int J Food Sci Technol. 50(1):169–177. https://doi.org/10.1111/ijfs.12618. Accessed 02 Dec 2021

Vuong Q, Hirun S, Phillips P, Chuen T, Bowyer M, Goldsmith C, Scarlett C (2014) Fruit-derived phenolic compounds and pancreatic cancer: Perspectives from Australian native fruits. J Ethnopharmacol 152(2): 227–242. Retrieved from http://ac.els-cdn.com/S0378874113009033/1-s2.0-S0378874113009033-main.pdf?_tid=c2cc1cc0-7e23-11e6-9460-00000aeb3f5f&acdnat=1474260453_a5424539a2c492ed0b1ac12d2de913f6

Wijaya YA, Widyadinata D, Irawaty W, Ayucitra A (2017) Fractionation of phenolic and flavonoid compounds from kaffir lime (Citrus hystrix) peel extract and evaluation of antioxidant activity. Reaktor 17(3):111–117